Europe Multiple Myeloma Therapeutics Market By Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal Doxorubicin (Doxil)) And Alkylating Agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), By Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic Trioxide (Trisenox), Plerixafor (Mozobil)) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

Europe Multiple Myeloma Therapeutics Market By Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal Doxorubicin (Doxil)) And Alkylating Agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), By Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic Trioxide (Trisenox), Plerixafor (Mozobil)) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

ID: 860 | Pages: 142 | October 2018 | Region: Europe


The Europe Multiple Myeloma Therapeutics Market was worth USD 1.98 billion in 2018 and estimated to be growing at a CAGR of 4.58%, to reach USD 2.47 billion by 2023. Europe is the second largest market among regions after North America.

The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2018 and 2023. As multiple myeloma is mostly irredeemable and is regularly characterised by a cycle of reduction and relapse, there is an acute need for new treatments for patients that work in distinctive and innovative ways.

Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.

The Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide  (Revlimid), Arsenic trioxide  (Trisenox), Plerixafor  (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.

Based on geography the market is analysed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at highest CAGR.

Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation

                5.1 By Treatment Type

                                5.1.1 Chemotherapy      

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide  (Revlimid)

                                                5.2.2.3 Arsenic trioxide  (Trisenox)

                                                5.2.2.4 Plerixafor  (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Pipeline Product Analysis                                        

                7.1 Overview

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Multiple Myeloma Therapeutics Market By Region, From 2018–2023 (USD Billion)
  2. Europe Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  3. Europe Chemotherapy Market By Region, From 2018–2023 (USD Billion)
  4. Europe Targeted Therapy Market By Region, From 2018–2023 (USD Billion)
  5. Europe Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  6. Europe Corticosteroids Market By Region, From 2018–2023 (USD Billion)
  7. Europe Immunomodulatory agents Market By Region, From 2018–2023 (USD Billion)
  8. U.K Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  9. U.K Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  10. Spain Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  11. Spain Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  12. Germany Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  13. Germany Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  14. Italy Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  15. Italy Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  16. France Multiple Myeloma Therapeutics Market By Treatment Type, From 2018–2023 (USD Billion)
  17. France Multiple Myeloma Therapeutics Market By Drug Type, From 2018–2023 (USD Billion)
  18. Europe Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  19. Europe Anthracycline Antibiotic Market By Region, From 2018–2023 (USD Billion)
  20. Europe Alkylating Agent Market By Region, From 2018–2023 (USD Billion)
  21. U.K Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  22. Spain Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  23. Germany Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  24. Italy Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  25. France Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  26. Europe Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  27. Europe Melphalan (Alkeran) Market By Region, From 2018–2023 (USD Billion)
  28. Europe Liposomal doxorubicin (Doxil) Market By Region, From 2018–2023 (USD Billion)
  29. U.K Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  30. Spain Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  31. Germany Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  32. Italy Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  33. France Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  34. Europe Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  35. Europe Doxorubicin (Adriamycin) Market By Region, From 2018–2023 (USD Billion)
  36. Europe Cyclophosphamide (Neosar) Market By Region, From 2018–2023 (USD Billion)
  37. Europe Vincristine (Oncovin) Market By Region, From 2018–2023 (USD Billion)
  38. Europe Carmustine (BiCNU) Market By Region, From 2018–2023 (USD Billion)
  39. U.K Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  40. Spain Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  41. Germany Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  42. Italy Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  43. France Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2018–2023 (USD Billion)
  44. Europe Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  45. Europe Bortezomib (Velcade) Market By Region, From 2018–2023 (USD Billion)
  46. Europe Carfilzomib (Kyprolis) Market By Region, From 2018–2023 (USD Billion)
  47. U.K Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  48. Spain Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  49. Germany Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  50. Italy Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  51. France Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2018–2023 (USD Billion)
  52. Europe Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  53. Europe Dexamethasone (Decadron) Market By Region, From 2018–2023 (USD Billion)
  54. Europe Prednisone (Deltasone/Orasone) Market By Region, From 2018–2023 (USD Billion)
  55. U.K Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  56. Spain Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  57. Germany Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  58. Italy Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  59. France Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2018–2023 (USD Billion)
  60. Europe Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
  61. Europe Thalidomide (Thalomid) Market By Region, From 2018–2023 (USD Billion)
  62. Europe Lenalidomide (Revlimid) Market By Region, From 2018–2023 (USD Billion)
  63. Europe Arsenic trioxide (Trisenox) Market By Region, From 2018–2023 (USD Billion)
  64. Europe Plerixafor (Mozobil) Market By Region, From 2018–2023 (USD Billion)
  65. U.K Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
  66. Spain Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
  67. Germany Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
  68. Italy Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
  69. France Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2018–2023 (USD Billion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2019 Market Data Forecast
All Rights Reserved.